Keywords
Pleomorphic cells
Surgery
Prognosis
How to Cite
Abstract
Osteoclast-like giant cell carcinoma of the pancreas is a rare carcinoma, so there is not much information available on its treatment in localized or advanced stages or on its prognosis, which seems to depend on the proportion of cell types present. The aim is to provide a review of the current state of knowledge about this type of carcinoma, illustrating two clinical cases with different biological behaviors, which reflects the heterogeneity of this tumour entity. In the first clinical case presented, the outcome is good despite early recurrence or persistence of carcinoma after surgery performed with curative intent; however, in the second clinical case, the outcome has been poor, without it being possible to propose any type of oncological therapeutic approach. The description and presentation of these cases to the scientific community provide further information with the aim of sharing knowledge and attempting to open up potential avenues of research.
References
Sommers SC, Meissner WA. Unusual carcinomas of the pancreas. AMA Arch Pathol. 1954 Aug;58(2):101-11.
Rosai J. Carcinoma of the pancreas simulating giant cell tumor of bone: electron-microscopic evidence of its acinar cell origin. Cancer. 1968;22:333-44. doi:10.1002/1097-0142(196808)22:23.0.CO;2-A.
Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole-exome sequencing analysis. BMC Gastroenterol. 2020;20:202. doi:10.1186/s12876-020-01351-7.
Luchini C, Pea A, Lionheart G, Mafficini A, Nottegar A, Veronese N, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. J Pathol. 2017;243:148-54. doi:10.1002/path.4941.
Swaid MB, Vitale E, Alatassi N, Siddiqui H, Yazdani H. Metastatic undifferentiated osteoclast-like giant cell pancreatic carcinoma. Cureus. 2022 Aug;14(8):e27586. doi:10.7759/cureus.27586.
Gao HQ, Yang YM, Zhuang Y, Liu P. Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: case report. World J Gastroenterol. 2015 Jan 14;21(2):694-8. doi:10.3748/wjg.v21.i2.694.
Obayashi M, Shibasaki Y, Koakutsu T, Hayashi Y, Shoji T, Hirayama K, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report. BMC Gastroenterol. 2020;20:220. doi:10.1186/s12876-020-01362-4
Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, et al. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer. 2020;20:946. doi:10.1186/s12885-020-07462-4.
Mylonakis A, Driva TS, Lykoudis P, Frountzas M, Machairas N, Tsapralis D, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: an individual participant data meta-analysis. Ann Hepatobiliary Pancreat Surg. 2024;28:125-33. doi:10.14701/ahbps.23-161.
Muraki T, Reid MD, Basturk O, Jang K-T, Bedolla G, Bagci P, et al. Undifferentiated carcinoma with osteoclastic giant cells of the pancreas: clinicopathological analysis of 38 cases highlights a more protracted clinical course than currently appreciated. Am J Surg Pathol. 2016 Sep;40(9):1203-16. doi:10.1097/PAS.0000000000000689.
Demetter P, Marechal R, Puleo F, Delhaye M, Debroux S, Charara F, et al. Undifferentiated pancreatic carcinoma with osteoclast-like giant cells: what do we know so far? Front Oncol. 2021;11:630086. doi:10.3389/fonc.2021.630086.
Yonemasu H, Takashima M, Nishiyama KI, Ueki T, Yao T, Tanaka M, et al. Phenotypical characteristics of undifferentiated carcinoma of the pancreas: comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, a-catenin and b-catenin expression. Oncol Rep. 2001;8:745-52. doi:10.3892/or.8.4.745.
Sano M, Homma T, Hayashi E, Noda H, Amano Y, Tsujimura R, et al. Clinicopathological characteristics of anaplastic carcinoma of the pancreas with rhabdoid features. Virchows Arch. 2014;465:531-8. doi:10.1007/s00428-014-1631-5.
Naito Y, Kawahara A, Taira T, Takase Y, Murata K, Ishida Y, et al. Cytopathological and immunocytochemical findings of pancreatic anaplastic carcinoma with ZEB1 expression by touch imprint cytology. Diagn Cytopathol. 2018;46:198-203. doi:10.1002/dc.23823.
Ishida K, Yamashita R, Osakabe M, Uesugi N, Yamada N, Nitta H, et al. Expression of epithelial-mesenchymal transition proteins in pancreatic anaplastic (undifferentiated) carcinoma. Pancreas. 2019 Jan;48(1):36-42. doi:10.1097/MPA.0000000000001199.
Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018 Feb 1;554(7690):62-8. doi:10.1038/nature25459.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Jorge del Río Fernández, Noelia Rodríguez Ferreiro, Adán Rodríguez González, Verónica Velasco Durántez, Miguel Carvajal Álvarez, Virginia Galeazzi Martínez, Teresa Sampedro Gimeno